Presenter: Prof. Spyridonidis
Participants:Dr Liga, Dr Valera, Dr Tsokanas
Duration: 40 mins


These Guidelines were developed by the European Hematology Association (EHA) and European Society for Medical Oncology (ESMO). The 2 societies nominated authors to write the guidelines as well as reviewers to comment on them. These guidelines were approved by the EHA Board and the ESMO Guidelines Committee in November 2020.

Highlights
• This EHA-ESMO Clinical Practice Guideline provides key
recommendations on the management of multiple myeloma
• Authorship includes a multidisciplinary group of experts
from different institutions and countries in Europe
• Key treatment recommendations are provided for both newly
diagnosed myeloma patients and patients with relapsed/
refractory disease
• Recommendations for the treatment of plasma cell leukaemia, solitary plasmacytoma and smouldering myeloma are
also provided
• Key recommendations for myeloma complications, including
bone disease and renal impairment, are included